The Feasibility Study of Adjuvant Chemotherapy with TS-1+Carboplatin followed by TS-1 maintenace in Patients with Completely Resected Stage II-IIIA Non-Small-Cell Lung Cancer
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000005041
- Lead Sponsor
- Setouchi Lung Cancer Group
- Brief Summary
Seventy-eight patients (89.7%) completed four cycles of S-1 plus carboplatin and 55 (63.2%) completed the following S-1 maintenance therapy for a total of 10 months. The treatment completion rate was 63.2% (90% CI, 54.4-71.2%), indicating feasibility. There were no treatment-related deaths. Grade 3/4 toxicities included neutropenia (13.8%), thrombocytopenia (11.5%), and anorexia (4.6%). The 2-year relapse-free survival rate was 59.8%.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 89
Not provided
1. Allergy against platinum-containing drugs or component of S-1 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, uncontrolled diabetes, ileus, diarrhea, hemorrhagic tendency) 3. Active infections 4. Massive pleural or pericardial effusion 5. Active simultaneous cancer 6. Active interstitial pneumonitis or its past history 6. Pregnant or lactating women 8. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility
- Secondary Outcome Measures
Name Time Method disease free survival, overall survival